Medleygenomics
1 known investors
Medley Genomics builds algorithms and software that profile tumor heterogeneity to guide individualized cancer diagnosis and therapy.
Also known as Medley Genomics · Medley Genomics Inc.
Investors · 1
Company profile
researched Aug 2026Medley Genomics Inc. is a Providence, Rhode Island-based biotechnology company that develops algorithms and software for analyzing genomic sequencing data in complex diseases, applied first in oncology. The company frames its output as the "molecular fingerprints" of an individual patient's cancer, intended to help oncologists arrive at individualized diagnoses and treatment selection, and to give pharmaceutical developers data for designing new therapeutics.
The company's stated technical focus is characterizing the heterogeneity of disease within a patient and defining disease mechanisms across patient cohorts. According to the company, these insights are needed to optimize targeted and combination therapies, personalized cancer vaccines and immunotherapies against the total disease burden. As of its Gust profile, Medley Genomics was at a prototype-ready stage with four employees and was incorporated as a C-corp.
Founding story
Medley Genomics was founded in August 2016 by Patrice Milos, Ph.D., who serves as co-founder, President and CEO, and Benjamin Raphael, Ph.D., a Princeton University computer science professor who serves as co-founder and Chief Technology Officer. Milos's background is in genomic technologies for precision healthcare, including next-generation sequencing and pharmacogenomics across drug discovery and development. David Potter joined as Executive Director of Commercialization, bringing prior roles as co-founder, senior officer or board-appointed consultant at seven healthcare analytics companies, including two exits.
Business model
Medley Genomics supplies algorithms and software rather than laboratory services, delivering analytic outputs to clinical and pharmaceutical users; its HotNet2 solution is distributed to researchers through the Lifebit CloudOS Marketplace.
Traction
As of its Gust profile the company reported prototype-ready stage and four employees. In 2019 the CEO stated that customers were increasingly applying HotNet2 to define patient subgroups and reveal novel biological pathways.
Latest developments
In November 2019 Medley Genomics and Lifebit Biotech announced a partnership making HotNet2 available at enterprise scale over distributed, federated datasets through Lifebit CloudOS and its marketplace.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company positions itself in precision oncology data analytics, addressing the interpretation gap created by falling genome sequencing costs and rapidly growing volumes of sequence data available for healthcare decisions.
Medley Genomics emphasizes network-based analysis of intra-tumor and cohort-level disease heterogeneity, including infrequently mutated genes, rather than single-gene or panel-style interpretation, with the aim of informing combination and immunotherapy strategies against total disease burden.
Technology
The company's core asset described publicly is HotNet2, an algorithm developed by co-founder Ben Raphael that assesses heterogeneous genomic landscapes across patient cohorts by constructing significantly mutated gene subnetworks from mutational frequencies and known interaction networks, including lower-frequency "long tail" disease-relevant genes. HotNet2 historically required a complex installation because of its many software dependencies; via the Lifebit CloudOS integration it runs over distributed data using federated analysis, so data is not transferred out of its secure environment, with report and visualization generation at scale. Customers were reported in 2019 to be using HotNet2 to define subgroups within patient disease cohorts and to identify novel biological pathways.
Go-to-market
In addition to direct customer relationships, the company distributes its analytics through partner platforms; the November 2019 Lifebit agreement placed HotNet2 in the Lifebit CloudOS Marketplace to reach researchers in the broader biomedical community.
Oncologists and clinical decision-makers seeking individualized diagnosis and treatment selection, pharmaceutical companies developing novel therapeutics, and biomedical researchers working with patient genomic cohorts.
Geography
Headquartered in Providence, Rhode Island, United States; its 2019 partner Lifebit Biotech is headquartered in London, UK.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $299.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 1
launches, deals, and filingsMedley Genomics and Lifebit Biotech announced a partnership agreement making Medley's HotNet2 algorithm deployable at enterprise scale over distributed patient cohort data using Lifebit CloudOS federated analysis, with availability through the Lifebit CloudOS Marketplace.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Medleygenomicsmedleygenomics.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medleygenomics do?
- Medley Genomics builds algorithms and software that profile tumor heterogeneity to guide individualized cancer diagnosis and therapy.
- Who are Medleygenomics's investors?
- Medleygenomics's investors include Slater Technology Fund.